Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity

Panel on Clinical Practices for Treatment of HIV Infection, 2000

Carpenter, 2000, Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society USA Panel, JAMA, 283, 381, 10.1001/jama.283.3.381

Eron, 1995, Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter, N Engl J Med, 333, 1662, 10.1056/NEJM199512213332502

Fischl, 1995, Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease, Ann Intern Med, 122, 24, 10.7326/0003-4819-122-1-199501010-00004

Katlama, 1996, Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: A randomized controlled comparison with zidovudine monotherapy, JAMA, 276, 118, 10.1001/jama.276.2.118

Delta Coordinating Committee, 1996, Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus ddI or zalcitabine with zidovudine alone in HIV-infected individuals, Lancet, 348, 283, 10.1016/S0140-6736(96)05387-1

Hammer, 1996, A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per millimeter, N Engl J Med, 335, 1081, 10.1056/NEJM199610103351501

Saravolatz, 1996, Zidovudine alone or in combination with ddI or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter, N Engl J Med, 335, 1099, 10.1056/NEJM199610103351503

Saag, 1998, Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults, AIDS, 12, F203, 10.1097/00002030-199816000-00002

Ruiz, 1996, Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC, AIDS, 10, F61, 10.1097/00002030-199612000-00003

Staszewski, 1998, A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects, AIDS, 12, F197, 10.1097/00002030-199816000-00001

Palella, 1998, Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, N Engl J Med, 338, 853, 10.1056/NEJM199803263381301

Zhang, 1999, Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy, N Engl J Med, 340, 1605, 10.1056/NEJM199905273402101

Brinkman, 2000, Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: A looming obstacle for long-term anti-retroviral therapy?, Curr Opin Infect Dis, 13, 5, 10.1097/00001432-200002000-00002

Scalfaro, 1998, Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment, Intensive Care Med, 24, 247, 10.1007/s001340050558

Blanche, 1999, Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues, Lancet, 354, 1084, 10.1016/S0140-6736(99)07219-0

Gervasoni, 1998, Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy, AIDS, 13, 465, 10.1097/00002030-199903110-00004

Saint-Marc, 1999, A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy, AIDS, 13, 1659, 10.1097/00002030-199909100-00009

Madge, 1999, Lipodystrophy in patients naive to HIV protease inhibitors, AIDS, 13, 735, 10.1097/00002030-199904160-00020

Lewis, 1995, Mitochondrial toxicity of antiviral drugs, Nat Med, 1, 417, 10.1038/nm0595-417

Brinkman, 1998, Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway, AIDS, 12, 1735, 10.1097/00002030-199814000-00004

Brinkman, 1999, Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy, Lancet, 354, 1112, 10.1016/S0140-6736(99)06102-4

Kakuda, 1999, Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy, AIDS, 13, 2311, 10.1097/00002030-199911120-00019

Noble, 1999, Adefovir dipivoxil, Drugs, 58, 479, 10.2165/00003495-199958030-00010

2000

Green, 1998, Mitochondria and apoptosis, Science, 281, 1309, 10.1126/science.281.5381.1309

Saraste, 1999, Oxidative phosphorylation at the fin de siècle, Science, 283, 1488, 10.1126/science.283.5407.1488

Johns, 1995, Mitochondrial DNA and disease, N Engl J Med, 333, 638, 10.1056/NEJM199509073331007

Wallace, 1999, Mitochondrial diseases in man and mouse, Science, 283, 1482, 10.1126/science.283.5407.1482

Simon, 1999, Mitochondrial disorders: Clinical and genetic features, Annu Rev Med, 50, 111, 10.1146/annurev.med.50.1.111

Chinnery, 1999, Mitochondrial DNA and disease, Lancet, 354, 17, 10.1016/S0140-6736(99)90244-1

Balzarini, 1994, Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives, Pharm World Sci, 16, 113, 10.1007/BF01880662

Rossi, 1999, Metabolism, mitochondrial uptake and toxicity of 2′,3′-dideoxycytidine, Biochem J, 344, 915, 10.1042/0264-6021:3440915

Faletto, 1997, Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89, Antimicrob Agents Chemother, 41, 1099, 10.1128/AAC.41.5.1099

Balzarini, 1989, Differential patterns of intracellular metabolism of 2′, 3′-didehydro-2′, 3′-dideoxythymidine (d4T) and 3′-azido-2′,3′-dideoxythymidine (AZT) , two potent anti-HIV compounds, J Biol Chem, 264, 6127, 10.1016/S0021-9258(18)83322-1

Bourdais, 1996, Cellular phosphorylation of anti-HIV nucleosides, J Biol Chem, 271, 7887, 10.1074/jbc.271.14.7887

Gao, 1993, Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells, J Clin Invest, 91, 2326, 10.1172/JCI116463

Gao, 1994, Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells, J Biol Chem, 269, 12633, 10.1016/S0021-9258(18)99923-0

Starnes, 1987, Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro, J Biol Chem, 262, 988, 10.1016/S0021-9258(19)75738-X

Copeland, 1992, Human DNA polymerases alpha and beta are able to incorporate anti-HIV deoxynucleotides into DNA, J Biol Chem, 267, 21459, 10.1016/S0021-9258(19)36631-1

Olivero, 1999, Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero, AIDS, 13, 919, 10.1097/00002030-199905280-00007

Cheng, 1990, DNA polymerases versus HIV reverse transcriptase in AIDS therapy, Ann N Y Acad Sci, 616, 217, 10.1111/j.1749-6632.1990.tb17842.x

Hart, 1992, Effects of (−) -2′-deoxy-3′-thiacytidine (lamivudine) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma, Antimicrob Agents Chemother, 36, 1688, 10.1128/AAC.36.8.1688

Martin, 1994, Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis, Antimicrob Agents Chemother, 38, 2743, 10.1128/AAC.38.12.2743

Naviaux, 1999, Sensitive assay for mitochondrial DNA polymerase γ, Clin Chem, 45, 1725, 10.1093/clinchem/45.10.1725

White, 1989, Comparison of the effect of carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases, Biochem Biophys Res Commun, 161, 393, 10.1016/0006-291X(89)92611-9

Izuta, 1991, The 5′-triphosphates of 3′-azido-3′-deoxythymidine and 2′ ,3′-dideoxynucleosides inhibit DNA polymerase gamma by different mechanisms, Biochem Biophys Res Commun, 179, 776, 10.1016/0006-291X(91)91884-F

Parker, 1991, Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases α, β, and γ by the 5′-triphosphates of carbovir, 3′-azido-3′-deoxythymidine, 2′,3′-dideoxyguanosine, and 3′-deoxythymidine, J Biol Chem, 266, 1754, 10.1016/S0021-9258(18)52360-7

Lewis, 1994, Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine, Circ Res, 74, 344, 10.1161/01.RES.74.2.344

Cherrington, 1995, Kinetic interaction of the diphosphates of 9-(2-phosphonyl-methoxyethyl) adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases α, β, and γ, Antiviral Chem Chemother, 6, 217, 10.1177/095632029500600403

Eriksson, 1995, Efficient incorporation of anti-HIV deoxynucleotides by recombinant yeast mitochondrial DNA polymerase, J Biol Chem, 270, 18929, 10.1074/jbc.270.32.18929

Kukhanova, 1996, Interaction of β-l-2′, 3′-dideoxy-2′ ,3′-didehydro-5-CTP with human immunodeficiency virus-1 reverse transcriptase and human DNA polymerases: Implications for human immunodeficiency virus drug design, Mol Pharmacol, 53, 801

Barile, 1994, Mechanisms of toxicity of 3′-azido-3′-deoxythymidine. Its interaction with adenylate kinase, Biochem Pharmacol, 48, 1405, 10.1016/0006-2952(94)90564-9

Barile, 1997, 3′-Azido-3′-deoxythmidine uptake into isolated rat liver mitochondria and impairment of ADP/ATP translocator, Biochem Pharmacol, 53, 913, 10.1016/S0006-2952(96)00831-3

Modica-Napolitano, 1993, AZT causes tissuespecific inhibition of mitochondrial bioenergetic function, Biochem Biophys Res Commun, 194, 170, 10.1006/bbrc.1993.1800

Elimadi, 1997, Differential effects of zidovudine and zidovudine triphosphate on mitochondrial permeability transition and oxidative phosphorylation, Br J Pharmacol, 121, 1295, 10.1038/sj.bjp.0701276

Pereira, 1998, Mitochondrial sensitivity to AZT, Cell Biochem Funct, 16, 173, 10.1002/(SICI)1099-0844(199809)16:3<173::AID-CBF783>3.0.CO;2-4

Chen, 1991, Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implications for delayed toxicity, Mol Pharmacol, 39, 625

Chen, 1992, The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the antihuman immunodeficiency virus compound, 2′,3′-dideoxycytidine, J Biol Chem, 267, 2856, 10.1016/S0021-9258(19)50661-5

Medina, 1994, Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides, Antimicrob Agents Chemother, 38, 1824, 10.1128/AAC.38.8.1824

Tsai, 1994, Effect of anti-HIV 2′-beta-fluoro-2′,3′-dideoxynucleoside analogs on the cellular content of mitochondrial DNA and on lactate production, Biochem Pharmacol, 48, 1477, 10.1016/0006-2952(94)90573-8

Parker, 1997, Lack of mitochondrial toxicity in CEM cells treated with carbovir, Antiviral Res, 34, 131, 10.1016/S0166-3542(97)01033-4

Chen, 1989, Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine, J Biol Chem, 264, 11934, 10.1016/S0021-9258(18)80156-9

Nusbaum, 1996, AZT incorporation into mitochondria: Study in a human myeloid cell line, DNA Cell Biol, 15, 363, 10.1089/dna.1996.15.363

Hobbs, 1992, The Friend murine erythroleukemia cell, a model system for studying the association between bone marrow toxicity induced by 3′-azido-3′-dideoxythymidine and dideoxynucleoside inhibition of mtDNA replication, Biochem Pharmacol, 43, 1397, 10.1016/0006-2952(92)90194-N

Hobbs, 1995, Cellular targets of 3′-azido-3′-deoxythymidine: An early (non-delayed) effect on oxidative phosphorylation, Biochem Pharmacol, 50, 381, 10.1016/0006-2952(95)00141-L

Herzberg, 1992, Major growth reduction and minor decrease in mitochondrial enzyme activity in cultured human muscle cells after exposure to zidovudine, Muscle Nerve, 15, 706, 10.1002/mus.880150613

Semino-Mora, 1994, Effect of l-carnitine on the zidovudine-induced destruction of human myotubes. Part I: l-carnitine prevents the myotoxicity of AZT in vitro, Lab Invest, 71, 102

Semino-Mora, 1994, The effect of l-carnitine on the AZT-induced destruction of human myotubes. Part II: Treatment with l-carnitine improves the AZT-induced changes and prevents further destruction, Lab Invest, 71, 773

Benbrik, 1997, Cellular and mitochondrial toxicity of zidovudine (AZT) , didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells, J Neurol Sci, 149, 19, 10.1016/S0022-510X(97)05376-8

Keilbaugh, 1993, Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: Prevention of 2′,3′-dideoxycytidine toxicity in PC12 cells, a neuronal model, by uridine and pyruvate, Mol Pharmacol, 44, 702

Keilbaugh, 1997, Effect of 2′,3′-dideoxycytidine on oxidative phosphorylation in the PC12 cell, a neuronal model, Biochem Pharmacol, 53, 1485, 10.1016/S0006-2952(97)82442-2

Cui, 1997, Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells, J Pharmacol Exp Ther, 280, 1228

Wang, 1996, Zidovudine and dideoxynucleosides deplete wild-type mitochondrial DNA levels and increase deleted mitochondrial DNA levels in cultured Kearns-Sayre syndrome fibroblasts, Biochim Biophys Acta, 1316, 51, 10.1016/0925-4439(96)00015-4

Schroder, 1996, Nuclear and mitochondrial changes of cocultivated spinal cord, spinal ganglia and muscle fibers following treatment with various doses of zidovudine, Acta Neuropathol, 92, 138, 10.1007/s004010050501

Lewis, 1991, Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts, Lab Invest, 65, 228

Youssef, 1992, Disruption of mitochondrial energetics and DNA synthesis by the anti-AIDS drug dideoxyinosine, Toxicol Lett, 60, 197, 10.1016/0378-4274(92)90274-N

Feldman, 1994, Schwann cell mitochondrial alterations in peripheral nerves of rabbits treated with 2′,3′-dideoxycytidine, Acta Neuropathol, 87, 71, 10.1007/BF00386256

Linnane, 1995, The universality of bioenergetic disease and amelioration with redox therapy, Biochim Biophys Acta, 1271, 191, 10.1016/0925-4439(95)00027-2

Corcuera, 1996, Hepatic morphological alterations induced by zidovudine (ZDV) in an experimental model, Pathol Res Pract, 192, 182, 10.1016/S0344-0338(96)80218-4

de la Asuncion, 1999, Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver, Hepatology, 29, 985, 10.1002/hep.510290353

Moyle, 1998, Peripheral neuropathy with nucleoside antiretrovirals: Risk factors, incidence and management, Drug Saf, 19, 481, 10.2165/00002018-199819060-00005

Gasnault, 1999, Subacute ascendant polyneuropathy revealing a nucleoside-induced mitochondrial cytopathy

Cooney, 1986, Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity, Biochem Pharmacol, 35, 2065, 10.1016/0006-2952(86)90571-X

Marra, 1997, Hearing loss and antiretroviral therapy in patients infected with HIV-1, Arch Neurol, 54, 407, 10.1001/archneur.1997.00550160049015

Perry, 1996, Didanosine: An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease, Drugs, 52, 928, 10.2165/00003495-199652060-00014

Dassopoulos, 1999, Acute pancreatitis in human immunodeficiency virus-infected patients: A review, Am J Med, 107, 78, 10.1016/S0002-9343(99)00169-2

Yarchoan, 1994, A randomized pilot study of alternating or simultaneous zidovudine and ddI therapy in patients with symptomatic human immunodeficiency virus infection, J Infect Dis, 169, 9, 10.1093/infdis/169.1.9

Allaouchiche, 1999, Acute pancreatitis with severe lactic acidosis in an HIV-infected patient on ddI therapy, J Antimicrob Chemother, 44, 137, 10.1093/jac/44.1.137

Hurst, 1999, Stavudine: An update of its use in the treatment of HIV infection, Drugs, 58, 919, 10.2165/00003495-199958050-00012

Kahn, 1999, Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial, JAMA, 282, 2305, 10.1001/jama.282.24.2305

Hayakawa, 1991, Massive conversion of guanosine to 8hydroxy-guanosine in mouse liver mitochondrial DNA by administration of azidothymidine, Biochem Biophys Res Commun, 176, 87, 10.1016/0006-291X(91)90893-C

Mhiri, 1991, Zidovudine myopathy: A distinctive disorder associated with mitochondrial dysfunction, Ann Neurol, 29, 606, 10.1002/ana.410290607

Corcuera Pindado, 1994, Histochemical and ultrastructural changes induced by zidovudine in mitochondria of rat cardiac muscle, Eur J Histochem, 38, 311

Thornberry, 1998, Caspases: Enemies within, Science, 281, 1312, 10.1126/science.281.5381.1312

Leoni, 1998, Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c, 95, 9567

Hashimoto, 1997, Stavudine selectively induces apoptosis in HIV type 1-infected cells, AIDS Res Hum Retroviruses, 13, 193, 10.1089/aid.1997.13.193

Domingo, 1999, Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy, AIDS, 13, 2261, 10.1097/00002030-199911120-00008

Lori, 1999, Hydroxyurea and HIV: 5 years later—from antiviral to immune-modulating effects, AIDS, 13, 1433, 10.1097/00002030-199908200-00001